Uncovering New Biomarkers for Prostate Cancer Through Proteomic and Network Analysis

Area of Science:

• Urology
• Oncology
• Proteomics

Background:

• Prostate cancer (PCa) is a prevalent malignancy globally and in the USA.
• Current biomarkers like prostate-specific antigen (PSA) have limitations in accurate PCa detection.
• Identifying novel biomarkers is crucial for improved PCa diagnosis and management.

Purpose of the Study:

• To identify novel urinary biomarkers for prostate cancer (PCa) detection.
• To correlate proteomic profiles with clinical and histopathological characteristics of PCa.
• To enhance the panel of biomarkers for improved PCa management.

Main Methods:

• Urine samples from healthy donors and PCa patients were analyzed using proteomic approaches.
• Proteomic data was integrated with The Cancer Genome Atlas (TCGA) database.
• In silico analysis assessed biomarker associations with clinical and histopathological features.

Main Results:

• Urinary proteome variations reflect PCa status, highlighting complement and coagulation cascades in low-risk and glutathione metabolism in high-risk PCa.
• New potential biomarkers including CPM, KRT8, ITIH2, and RCN1 were identified.
• Findings align with existing literature, supporting their validity.

Conclusions:

• The identified biomarkers enhance understanding of PCa.
• These novel markers can potentially improve PCa management strategies.
• Further validation in larger patient cohorts is necessary.